Rafferty Asset Management, LLC Humanigen, Inc Transaction History

Rafferty Asset Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 10, 2022	SELL	$3.66 - $8.22 $1.66 Million - $3.72 Million	-452,912 Closed	0 $0
Q3 2021 Nov 10, 2021	BUY	$5.93 - $17.83 $1.95 Million - $5.87 Million	329,348 Added 266.54%	452,912 $2.69 Million
Q2 2021 Aug 10, 2021	SELL	$13.54 - $22.74 $1.13 Million - $1.9 Million	-83,765 Reduced 40.4%	123,564 $2.15 Million
Q1 2021 May 10, 2021	BUY	$12.91 - $23.83 $2.68 Million - $4.94 Million	207,329 New	207,329 $3.96 Million

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.